Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:CARA

Cara Therapeutics (CARA) Stock Price, News & Analysis

Cara Therapeutics logo

About Cara Therapeutics Stock (NASDAQ:CARA)

Key Stats

Today's Range
N/A
50-Day Range
$13.29
$17.10
52-Week Range
N/A
Volume
237,144 shs
Average Volume
22,224 shs
Market Capitalization
$24.33 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Cara Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
5th Percentile Overall Score

CARA MarketRank™: 

Cara Therapeutics scored higher than 5% of companies evaluated by MarketBeat, and ranked 950th out of 958 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for Cara Therapeutics.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Cara Therapeutics is -0.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Cara Therapeutics is -0.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Short Interest

    There is no current short interest data available for CARA.
  • Dividend Yield

    Cara Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Cara Therapeutics does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for CARA.
  • Search Interest

    5 people have searched for CARA on MarketBeat in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Cara Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 3.10% of the stock of Cara Therapeutics is held by insiders.

  • Percentage Held by Institutions

    44.66% of the stock of Cara Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Cara Therapeutics' insider trading history.
Receive CARA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cara Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

CARA Stock News Headlines

Warren Buffett Issues Cryptic Warning on U.S. Dollar
Imagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA or Bitcoin, but by owning a simple index fund. It sounds impossible. Yet it happened – just a short time ago. Now a legendary figure says: "Brace yourselves. It's about to happen here, in America. But fair warning – it could be the worst thing that ever happens to you." This story has received little coverage in the press. But if history repeats, it could bump tens of millions of Americans into a 7-figure net worth practically overnight.tc pixel
Cara Therapeutics board approves 1-for-3 reverse stock split
See More Headlines

CARA Stock Analysis - Frequently Asked Questions

Cara Therapeutics, Inc. (NASDAQ:CARA) posted its earnings results on Wednesday, August, 14th. The biopharmaceutical company reported ($13.32) earnings per share for the quarter, missing analysts' consensus estimates of ($9.72) by $3.60. The biopharmaceutical company had revenue of $0.99 million for the quarter, compared to analysts' expectations of $1.26 million. Cara Therapeutics had a negative net margin of 1,099.76% and a negative trailing twelve-month return on equity of 367.97%.

Cara Therapeutics's stock reverse split on the morning of Wednesday, April 16th 2025.The 1-3 reverse split was announced on Monday, April 14th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, April 15th 2025. An investor that had 100 shares of stock prior to the reverse split would have 33 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some other companies that Cara Therapeutics investors own include LIONS GATE ENTERTAINMENT CORP /CN/ (LGF.A), NVIDIA (NVDA), Canopy Growth (CGC), Advanced Micro Devices (AMD), Meta Platforms (META), First Solar (FSLR) and Tesla (TSLA).

Company Calendar

Last Earnings
8/14/2024
Today
9/17/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:CARA
CIK
1346830
Employees
80
Year Founded
2004

Profitability

EPS (Trailing Twelve Months)
($21.01)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$118.51 million
Net Margins
-1,099.76%
Pretax Margin
-1,099.76%
Return on Equity
-367.97%
Return on Assets
-107.43%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
4.77
Quick Ratio
4.71

Sales & Book Value

Annual Sales
$7.14 million
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$12.58 per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
4,574,000
Free Float
4,429,000
Market Cap
$24.33 million
Optionable
Optionable
Beta
0.41

Social Links

7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

This page (NASDAQ:CARA) was last updated on 9/17/2025 by MarketBeat.com Staff
From Our Partners